- Home
- ELE vs ERAS Comparison
ELE vs ERAS Comparison
Compare ELE & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ELE | ERAS |
|---|---|---|
| Founded | N/A | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | ELE | ERAS |
|---|---|---|
| Price | $19.22 | $12.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $5.78 |
| AVG Volume (30 Days) | 417.9K | ★ 8.4M |
| Earning Date | 03-30-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.82 | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $33,115,000.00 | N/A |
| Revenue This Year | $146.47 | N/A |
| Revenue Next Year | $57.23 | N/A |
| P/E Ratio | $229.19 | ★ N/A |
| Revenue Growth | ★ 124.30 | N/A |
| 52 Week Low | $7.80 | $1.01 |
| 52 Week High | $26.96 | $12.24 |
Technical Indicators
Market Signals| Indicator | ELE | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 85.20 |
| Support Level | $18.30 | $9.05 |
| Resistance Level | $22.09 | $10.71 |
| Average True Range (ATR) | 2.03 | 0.79 |
| MACD | -0.34 | 0.04 |
| Stochastic Oscillator | 9.01 | 96.32 |
Price Performance
Historical ComparisonAbout ELE Elemental Royalty Corporation
Elemental Royalty Corp is engaged in exploration discovery, royalty generation, royalty acquisition, and strategic investments.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.